Turn Biotechnologies Licenses Revolutionary Technology to Unwind the Effects of Aging at a Cellular Level
Turn Biotechnologies, a Shanda VC portfolio company developing medicines for currently untreatable age-related conditions, announced that it has acquired the global rights for new technology that reprograms cells to undo many of the effects of aging.
WhizAI Closes New Round with Investment from Shanda Group and AmerisourceBergen Bringing Total Capital Raised to $21 MillionSOMERSET, N.J.–(BUSINESS WIRE)–WhizAI, the first and only augmented analytics platform purpose built for the life sciences and healthcare industries, has […]
Foundation Capital Invests in Vibe Capital, a New Venture Firm Built for Scrappy International FoundersLimited partners in Vibe Capital include Bessemer Venture Partners, Tribe Capital and Foundation Capital, as well as individuals including GSV […]
Digital therapy maker Pear Therapeutics shakes the money tree, with plans to go public in $1.6B SPAC dealOne of Shanda’s portfolio companies, the digital treatment developer Pear Therapeutics, is taking the SPAC track, going public through a […]